Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to -$10.3 million.

  • vTv Therapeutics' Consolidated Net Income fell 7714.04% to -$10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.4 million, marking a year-over-year decrease of 2496.81%. This contributed to the annual value of -$22.7 million for FY2024, which is 1255.87% up from last year.
  • vTv Therapeutics' Consolidated Net Income amounted to -$10.3 million in Q3 2025, which was down 7714.04% from -$7.4 million recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' Consolidated Net Income ranged from a high of -$841000.0 in Q2 2021 and a low of -$10.3 million during Q3 2025
  • Its 5-year average for Consolidated Net Income is -$6.1 million, with a median of -$6.0 million in 2024.
  • The largest annual percentage gain for vTv Therapeutics' Consolidated Net Income in the last 5 years was 8314.97% (2021), contrasted with its biggest fall of 69010.58% (2021).
  • vTv Therapeutics' Consolidated Net Income (Quarter) stood at -$9.5 million in 2021, then soared by 35.78% to -$6.1 million in 2022, then grew by 27.08% to -$4.4 million in 2023, then grew by 0.09% to -$4.4 million in 2024, then tumbled by 133.15% to -$10.3 million in 2025.
  • Its Consolidated Net Income stands at -$10.3 million for Q3 2025, versus -$7.4 million for Q2 2025 and -$6.2 million for Q1 2025.